Aimed Bio에임드바이오

Aimed Bio reports strong trailing profit from licensing income, but its shares trade at very high multiples to those earnings.

Aimed Bio is a Korean biotech developing antibody-drug conjugate cancer therapies, mostly licensing early candidates to global drugmakers. Trailing results to H1 2026 show revenue of ₩47.3B, operating income of ₩20.8B and net income of ₩5.0B, with ₩30.2B in cash and very low borrowings. The share price is ₩21,800, far below its 52-week high of ₩80,200 and well above the model's base fair value of ₩5,978.

What stands out

• Trailing operating margin is 43.9%, but net margin is 10.6%, so a large part of operating profit did not carry through to net income.
• Valuation is extreme: P/E about 283 and P/B about 6.9, compared with peers such as Yuhan at about 25 and Samsung Biologics at about 34.
• The company's own discounted cash flow model gives a base value of ₩5,978, a bear case of ₩4,624 and a bull case of ₩8,138, below the current price in all cases.
• Foreign ownership rose from 2.1% to 3% over about 60 days, while retail and foreign investors were net sellers over the last 20 days and institutions were net buyers.
• Recent headlines cite a milestone as Boehringer Ingelheim's ADC enters clinical stage, which is a partner-driven development step rather than confirmed revenue.

What to watch

• A filing titled 'Major management matter relevant to investors' dated 2026-10-27 has appeared, but its content is not in the data; check the filing itself.
• Whether licensing income continues, since the trailing results rely on partner deals and the data does not show a revenue growth rate for 2025.
• Upcoming full-year results and any new licensing or milestone payments from partners such as Boehringer Ingelheim, Biohaven and SK Plasma.